Navigation Links
Lumenis' UltraPulse TotalFX Treatment Featured on ABCNews 20/20 as a Secret Weapon for Treating for Burn Scars
Date:7/20/2009

SANTA CLARA, Calif., July 20 /PRNewswire/ -- Lumenis Ltd., the world's largest medical laser company, announced today that their UltraPulse TotalFX treatment was featured on 20/20 on Friday, July 17(th) 2009, as a "secret weapon" to improve the texture, flexibility and appearance of severe scars from traumatic injuries.

The comprehensive feature chronicled the personal stories of survival of Chandra, Trae and Jordan Berns, who at just 17 months old were burned by a devastating arson fire that claimed the life of their mother. The triplets have lived with the reminder of that horrible night ever since and now, at the age of 22, they have found new hope in Lumenis' Ultrapulse Laser. After a total of three treatments, by Dr. Jill Waibel using the Ultrapulse, the triplets have all noticed significant reduction in the appearance of scars on their arms, chest, back and face and should continue to see further results in the next few months. In addition to cosmetic improvements, they have experienced improved flexibility and mobility in their arms and other areas of their bodies.

A pioneer in treating burns, Dr. Jill Waibel of the Palm Beach Aesthetic Dermatology & Laser Center in Palm Beach, Florida is very sympathetic to the emotional journey of burn victims and stated, "Scarring can be psychologically traumatic for any patient ... bad scars remind the patient over and over about the event that caused the injury."

Thick, deep, and inflexible, burn scars such as those shared by the Berns triplets are the most difficult skin wounds to treat, and although physicians and scientists have worked for years seeking out new treatment options, including other lasers, nothing has been effective on these severe burn scars until now.

Dr. Waibel's new "secret weapon" in treating scars is Lumenis' UltraPulse TotalFX laser. Commonly used for other cosmetic conditions such as deep wrinkles and unwanted pigment, Dr. Waibel discovered that this system could also be used to treat burn scars. The UltraPulse laser uses two different methods of treating the skin as well as a unique delivery to stimulate new collagen growth, lighten dark colors on the scar and remove some of the scar tissue.

"We literally take the scar out, and as a result new collagen is stimulated and formed. We not only improve the scar -- we create new healthy skin where there was a scar," explained Dr. Waibel. "We are able to treat scars that we were never able to treat before."

"Lumenis is excited to support the triplets' treatments along with Dr. Waibel's exciting work in scar revision, but most importantly to provide hope for Chandra, Trae and Jordan where they had no options before," stated Mr. Dov Ofer, CEO of Lumenis. "The company is grateful for the significant efforts of all of the physicians and nurses at the Palm Beach Aesthetic Dermatology & Laser Center especially that of Dr. Waibel and Dr. Kenneth Beer its founder".

"The significant improvement in the appearance of the triplets' scars has generated profound interest in using UltraPulse technology in improving the quality of life for burn survivors around the globe. The treatment offers hope for many since it is far less traumatic than traditional surgical revision of scars, results can be seen within a few weeks and the skin continues to improve for up to six months following treatment," added Mr. Robert Mann, SVP and General Manager of Lumenis Aesthetic Business.

Motivated to share their success with others, Chandra, Trae and Jordan have also started a foundation to help burn survivors cover the cost of their treatments which is called "Three For Hope" (read more about the Berns Triplets www.bernstriplets.com and the Ultrapulse treatments featured on Lumenis website: www.aesthetic.lumenis.com

About Lumenis

Lumenis Ltd., the world's leading medical laser company is a global developer, manufacturer and seller of laser, light-based and radiofrequency devices for surgical, aesthetic and ophthalmic applications, with more than 800 employees globally. Lumenis has over 250 patents worldwide, over 75 FDA clearances, worldwide presence in over 100 countries, and an installed base of over 70,000 systems. For more information about Lumenis and its products, please go to: www.lumenis.com.

Lumenis((R)) is a registered trademark of Lumenis Ltd.

    Contacts: Charly Rok                  Michelle Maydan
              Lippe Taylor                Director of Corporate Communications
              Office: 212-598-4400 x155   Lumenis
              Cell:  917-912-2863         Toll-free: 1-866-569-0597
              charly@lippetaylor.com      Office: +972-4-959-9004
                                          mmaydan@lumenis.com

Certain statements and information in this press release may be deemed to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, statements that contain projections of results of operations or of financial condition and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Forward-looking statements are often characterized by the use of forward-looking terminology such as "may," "will," "expect," "anticipate," "estimate," "continue," "believe," "should," "intend," "project" or other similar words, but are not the only way these statements are identified. We have based these forward-looking statements on assumptions and assessments made by our management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. Any forward-looking statements in this press release are made as of the date hereof, and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements may be found in our most recent Annual Report on Form 20-F, including the section therein entitled "Risk Factors", as well in our reports on Form 6-K, filed with the Securities and Exchange Commission.


'/>"/>
SOURCE Lumenis Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lumenis High Speed LightSheer(R) Duet(TM) Featured in New York Times Fashion & Style for Eliminating Pain and Nuisance of Hair Removal for Men
2. Lumenis Completes $15 Million Equity Financing From New and Existing Investors
3. Lumenis High Speed LightSheer(R) Duet(TM) Featured on ABCs Good Morning America Health as the New Gold Standard for Laser Hair Removal
4. Lumenis(R) Presents the SlimLine(TM) GI Laser Fiber: The Latest Advancement in Laser Lithotripsy for Gastroenterology
5. Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show
6. Lumenis Introduces the HoLEP Simulator and the PolyScope Disposable Ureteroscope at American Urology Association 2009 Annual Meeting
7. Lumenis(R) UltraPulse CO2 Laser to be Featured on National Television with Live Pearly Penile Papules (PPP) Procedure
8. Lumenis(R) UltraPulse CO2 Laser to be Featured on National Television with Live Pearly Penile Papule (PPP) Procedure
9. Lumenis(R) Introduces LightSheer(R) Duet(TM) for High Speed Permanent Hair Reduction
10. Lumenis(R) Introduces Four New Products & Delivery Devices at the 2008 American Academy of Ophthalmology Annual Meeting in Atlanta, Georgia USA
11. Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... ... February 13, 2016 , ... Good news ... first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, imaging ... as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just a ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a ... multitude of reasons. IsoPasta by Isolator Fitness has delved into this niche allowing ... without the high-carb repercussions. IsoPasta has 30 grams of protein and only 7 ...
(Date:2/13/2016)... ... February 13, 2016 , ... Christie Medical ... in-kind gift of a VeinViewer® Vision vein finder for the nursing ... start an IV and draw blood, combining technology with traditional technique. , “VeinViewer ...
(Date:2/12/2016)... ... 2016 , ... According to an article published February 4th on ... portion of hernia repairs throughout the United States. Commenting on this article, Beverly Hills ... this trend has not only been expected, but it seems to be a natural ...
(Date:2/12/2016)... Raton, FL (PRWEB) , ... February 12, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted over 250 members of South Florida’s philanthropic community at its ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , 12 februari 2016 AAIPharma ... toonaangevende leverancier van productie en ontwikkeling op ... kondigt vandaag een uitbreiding aan van steriele ... locatie in Charleston, SC ... tot meerdere recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... , Feb. 11, 2016 Stem cells ... are characterized by self-renewal and the capacity to differentiate ... relatively new discovery, as the first mouse embryonic stem ... was not until 1995 that the first culturing of ... stem cells were not produced until 2006 As a ...
Breaking Medicine Technology: